Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terlipressin infusion for variceal bleeding
NCT03130127Not yet recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Peptides, Small Molecules
01
Overview
Open-label trial of terlipressin in esophageal and gastric varices and Portal Hypertension (PH) (2 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: 5-day treatment failure. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
terlipressin
03
Conditions
esophageal and gastric varicesPortal Hypertension (PH)
Beyond the preview
Go deeper on NCT03130127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03130127.